Results 41 to 50 of about 31,381 (233)

LncRNA CCAT1 enhances chemoresistance in hepatocellular carcinoma by targeting QKI-5

Scientific Reports, 2022
A major reason for treatment failure of cancer is acquisition of drug resistance. The specific mechanisms underlying hepatocellular carcinoma (HCC) chemoresistance need to be fully elucidated.
Chongsheng Xia, Yurui Sun, Yang Li, Junli Ma, Jing Shi   +4 more
doaj   +1 more source

HOTAIR/miR-1277-5p/ZEB1 axis mediates hypoxia-induced oxaliplatin resistance via regulating epithelial-mesenchymal transition in colorectal cancer

Cell Death Discovery, 2022
The hypoxic microenvironment contributes to the chemoresistance of many malignant tumors including colorectal cancer (CRC). Accumulating studies have indicated that long non-coding RNAs (lncRNAs) play important roles in chemotherapy resistance.
Xingyue Weng, Hao Liu, Jian Ruan, Miaoyan Du, Lingjie Wang, Jiayan Mao, Ying Cai, Xuemei Lu, Wei Chen, Yaqing Huang, Xiao Zhi, Jianzhen Shan   +11 more
doaj   +1 more source

Role of autophagy in resistance to oxaliplatin in hepatocellular carcinoma cells

Oncology Reports, 2011
In spite of an initially promising anti-tumor activity, oxaliplatin-based combinatorial treatments can eventually result in a tumor resistance response. In this study we aimed to understand the role of autophagy in HCC cell resistance to oxaliplatin and to discuss its potential therapeutic implication. We found
Hailei, Du, Weiping, Yang, Lin, Chen, Mingming, Shi, Varun, Seewoo, Jiayu, Wang, Andy, Lin, Zhuoran, Liu, Weihua, Qiu   +8 more
openaire   +3 more sources

CHK2 activation contributes to the development of oxaliplatin resistance in colorectal cancer

British Journal of Cancer, 2022
Abstract Background Colorectal cancer (CRC), the most common cancer type, causes high morbidity and mortality. Patients who develop drug resistance to oxaliplatin-based regimens have short overall survival. Thus, identifying molecules involved in the development of oxaliplatin resistance is critical for designing ...
Chi-Che Hsieh, Sen-Huei Hsu, Chih-Yu Lin, Hung-Jiun Liaw, Ting-Wei Li, Kuan-Ying Jiang, Nai-Jung Chiang, Shang-Hung Chen, Bo-Wen Lin, Po-Chuan Chen, Ren-Hao Chan, Peng-Chan Lin, Yu-Min Yeh, Che-Hung Shen   +13 more
openaire   +2 more sources

Role of AMPK in Regulation of Oxaliplatin-Resistant Human Colorectal Cancer

Biomedicines, 2022
Oxaliplatin is a platinum analog that can interfere with DNA replication and transcription. Continuous exposure to oxaliplatin results in chemoresistance; however, this mechanism is not well known. In this study, oxaliplatin-resistant (OR) colorectal cancer (CRC) cells of HCT116, HT29, SW480 and SW620 were established by gradually increasing the drug ...
Sun Young Park, Ye Seo Chung, So Yeon Park, So Hee Kim   +3 more
openaire   +3 more sources

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

ANXA3 deletion inhibits the resistance of lung cancer cells to oxaliplatin.

European review for medical and pharmacological sciences, 2020
The purpose of this study was to explore the role of ANXA3 in lung cancer cell resistance to oxaliplatin (OXA).After adding different concentrations of Ox, A549, and A549/Ox cell viability were examined using cell counting kit-8 (CCK-8) assay, and the mRNA and protein expressions of ANXA3 were analyzed by quantitative Real Time-Polymerase Chain ...
Jin, Y.-F., Huang, Y.-T., Chen, P.-F.
openaire   +2 more sources

TRIM25 regulates oxaliplatin resistance in colorectal cancer by promoting EZH2 stability [PDF]

Cell Death & Disease, 2020
Abstract Resistance to chemotherapy remains the major cause of treatment failure in patients with colorectal cancer (CRC). Here, we identified TRIM25 as an epigenetic regulator of oxaliplatin (OXA) resistance in CRC. The level of TRIM25 in OXA-resistant patients who experienced recurrence during the follow-up period was significantly ...
Sha Zhou, Jianhong Peng, Liuniu Xiao, Caixia Zhou, Yujing Fang, Qingjian Ou, Jiayi Qin, Mengzhong Liu, Zhizhong Pan, Zhenlin Hou   +9 more
openaire   +5 more sources

UiO‐66 metal–organic frameworks in biomedicine: From structural tunability to bioimaging, photodiagnostics, and photodynamic cancer therapy

FEBS Open Bio, EarlyView.
UiO‐66(Zr) metal–organic frameworks are chemically stable, biocompatible, and highly tunable nanomaterials. Their modular structure enables controlled drug delivery, multimodal bioimaging, and light‐activated photodynamic therapy, supporting integrated diagnostic and therapeutic (theranostic) applications in cancer and biomedical research.
Veronika Huntošová, Grigorii Rakhalskii, Miroslav Almáši   +2 more
wiley   +1 more source

Acquired resistance to oxaliplatin is not directly associated with increased resistance to DNA damage in SK-N-ASrOXALI4000, a newly established oxaliplatin-resistant sub-line of the neuroblastoma cell line SK-N-AS.

PLoS ONE, 2017
The formation of acquired drug resistance is a major reason for the failure of anti-cancer therapies after initial response. Here, we introduce a novel model of acquired oxaliplatin resistance, a sub-line of the non-MYCN-amplified neuroblastoma cell line
Emily Saintas, Liam Abrahams, Gulshan T Ahmad, Anu-Oluwa M Ajakaiye, Abdulaziz S H A M AlHumaidi, Candice Ashmore-Harris, Iain Clark, Usha K Dura, Carine N Fixmer, Chinedu Ike-Morris, Mireia Mato Prado, Danielle Mccullough, Shishir Mishra, Katia M U Schöler, Husne Timur, Maxwell D C Williamson, Markella Alatsatianos, Basma Bahsoun, Edith Blackburn, Catherine E Hogwood, Pamela E Lithgow, Michelle Rowe, Lyto Yiangou, Florian Rothweiler, Jindrich Cinatl, Richard Zehner, Anthony J Baines, Michelle D Garrett, Campbell W Gourlay, Darren K Griffin, William J Gullick, Emma Hargreaves, Mark J Howard, Daniel R Lloyd, Jeremy S Rossman, C Mark Smales, Anastasios D Tsaousis, Tobias von der Haar, Mark N Wass, Martin Michaelis   +39 more
doaj   +1 more source